Capstone Investment Advisors
RARE icon

Capstone Investment Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Capstone Investment Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$549K Buy
16,457
+660
+4% +$16.4K ﹤0.01% 1199
2026
Q1 		$331K Buy
+15,797
New +$356K ﹤0.01% 1324
2024
Q4 		– Sell
-13,089
Closed -$727K – 1983
2024
Q3 		$727K Buy
+13,089
New +$667K ﹤0.01% 1087
2024
Q2 		– Sell
-4,863
Closed -$227K – 2392
2024
Q1 		$227K Buy
+4,863
New +$229K ﹤0.01% 1962

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Capstone Investment Advisors's RARE Position: Q2 2026 in Review

Capstone Investment Advisors increased its Ultragenyx Pharmaceutical (RARE) stake by 4.2% in Q2 2026, buying an estimated $16.4K and bringing the position to 16,457 shares worth $549K. The position accounts for ﹤0.01% of the portfolio, ranked #1199.

Capstone Investment Advisors first reported a position in RARE in Q1 2024 and has held it in 4 quarters since. The position peaked at $727K in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Capstone Investment Advisors held 16,457 shares of Ultragenyx Pharmaceutical worth $549K as of Q2 2026.
  • Capstone Investment Advisors bought 660 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $16.4K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1199 holding.
  • Capstone Investment Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and has held it in 4 quarters since.
  • Capstone Investment Advisors's Ultragenyx Pharmaceutical position peaked at $727K in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.